Kelly McGlynn

Kelly McGlynn, Ph.D. has a diverse and impressive work experience. In 2012, they began their career at the University of Rochester School of Medicine and Dentistry as a Postdoctoral Researcher, where they studied the role of the H4K20me3 histone methyltransferase Suv420h2 in TGF-beta-driven EMT. Kelly then worked as a Ph.D. Candidate, spearheading three projects involving characterization of a transcription factor/histone methyltransferase enzyme and its role in leukemia and normal hematopoiesis. In 2020, they became a Clinical Data Analyst at AmerisourceBergen, where they published an ASCO 2021 abstract on biosimilar utilization based on analysis of real-world drug administration data and trends in provider prescribing. That same year, they were also a Health Data Science Fellow at Insight Data Science. In 2021, they joined Constellation Pharmaceuticals as a Scientist I, where they were focused on mechanism of action and biomarker research related to ongoing Ph2 trial (small molecule BET inhibitor) for the treatment of myeloproliferative neoplasms. Currently, Kelly is a Scientist II at MOMA Therapeutics, where they are a key biologist on 2 pre-clinical oncology drug discovery programs, designing and performing lead-optimization and biomarker development experiments, and mechanism of action studies, as well as managing external activities at CRO partners.

Kelly McGlynn, Ph.D. received their B.S. in Cellular and Molecular Biology from the University of Wisconsin-La Crosse. Kelly then went on to obtain their Ph.D. in Molecular Pharmacology from the University of Rochester in 2018.